Inmune Bio (INMB) Invested Capital (2017 - 2025)
Historic Invested Capital for Inmune Bio (INMB) over the last 9 years, with Q3 2025 value amounting to $25.4 million.
- Inmune Bio's Invested Capital fell 3835.65% to $25.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.4 million, marking a year-over-year decrease of 3835.65%. This contributed to the annual value of $47.1 million for FY2024, which is 51.33% down from last year.
- Per Inmune Bio's latest filing, its Invested Capital stood at $25.4 million for Q3 2025, which was down 3835.65% from $28.9 million recorded in Q2 2025.
- In the past 5 years, Inmune Bio's Invested Capital registered a high of $90.6 million during Q1 2022, and its lowest value of $25.4 million during Q3 2025.
- Its 5-year average for Invested Capital is $54.8 million, with a median of $53.9 million in 2023.
- Per our database at Business Quant, Inmune Bio's Invested Capital skyrocketed by 18365.76% in 2021 and then plummeted by 4318.27% in 2024.
- Quarter analysis of 5 years shows Inmune Bio's Invested Capital stood at $80.2 million in 2021, then fell by 18.85% to $65.1 million in 2022, then decreased by 27.29% to $47.3 million in 2023, then dropped by 0.51% to $47.1 million in 2024, then tumbled by 46.12% to $25.4 million in 2025.
- Its Invested Capital was $25.4 million in Q3 2025, compared to $28.9 million in Q2 2025 and $29.7 million in Q1 2025.